Symbols / SER $1.56 -4.29% Serina Therapeutics, Inc.
SER Chart
Stock Fundamentals
|
|
|
|
|
|
About
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Ratings
Current target
$1.56
Low
$11.00
High
$11.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-28 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-07-14 | init | HC Wainwright & Co. | — → Buy | $15 |
| 2025-03-11 | init | Jones Trading | — → Buy | $11 |
News
RSS: Latest SER news- EAGLE POINT CREDIT COMPANY INC 6.5% SER C TERM PREFERRED STOCK DUE 2031 To Go Ex-Dividend On July 13th, 2026 With 0.13542 USD Dividend Per Share - 富途牛牛 Wed, 13 May 2026 06
- SER Stock Price and Chart — AMEX:SER - TradingView hu, 26 Mar 2026 07
- $SER stock is up 39% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
- Serina CEO speaks at Roth Conference today; replay lasts 90 days - Stock Titan ue, 24 Mar 2026 07
- Best Financial Stocks for 2026 and How to Invest - The Motley Fool Fri, 08 May 2026 19
- Ser Educacional S.A. stock (BRSEERACNOR5): Recent financial results and market position - AD HOC NEWS Wed, 13 May 2026 10
- Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why - Benzinga hu, 19 Mar 2026 07
- Serina Therapeutics (SER) Stock Jumps 39% Following $63M Financing Deal and Leadership Announcement - MEXC hu, 19 Mar 2026 07
- SER Stock Surges Amid Strategic Acquisitions and Partnerships - StocksToTrade hu, 19 Mar 2026 07
- Serina Therapeutics stock soars after FDA clears IND for Parkinson’s drug - Investing.com Wed, 28 Jan 2026 08
- This Is Why Serina Therapeutics Stock (SER) Rocketed Today - TipRanks hu, 29 Jan 2026 08
- Serina Therapeutics (SER) director granted 59,667 dividend shares - Stock Titan ue, 21 Apr 2026 07
- Parkinson's drug trial gets up to $30M as Serina adds board co-chair - Stock Titan Wed, 18 Mar 2026 07
- Sio Capital (SER) reports 1,000,000 shares, 6.71% stake in Serina Therapeutics - Stock Titan Mon, 04 May 2026 07
- Director at Serina Therapeutics (SER) receives 7,553 share grant - Stock Titan ue, 21 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
3.00
+500.00%
|
0.50
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
3.00
+500.00%
|
0.50
|
| Operating Expense |
|
24.02
+40.91%
|
17.05
+178.15%
|
6.13
+121.23%
|
2.77
|
| Research And Development |
|
13.15
+75.87%
|
7.48
+213.23%
|
2.39
+51.80%
|
1.57
|
| Selling General And Administration |
|
11.00
+14.27%
|
9.62
+147.15%
|
3.89
+202.15%
|
1.29
|
| General And Administrative Expense |
|
11.00
+14.27%
|
9.62
+147.15%
|
3.89
+202.15%
|
1.29
|
| Other Gand A |
|
11.00
+14.27%
|
9.62
+147.15%
|
3.89
+202.15%
|
1.29
|
| Other Operating Expenses |
|
-0.13
-132.14%
|
-0.06
+63.40%
|
-0.15
-67.21%
|
-0.09
|
| Total Expenses |
|
24.02
+40.91%
|
17.05
+178.15%
|
6.13
+121.23%
|
2.77
|
| Operating Income |
|
-24.02
-40.91%
|
-17.05
-444.84%
|
-3.13
-37.82%
|
-2.27
|
| Total Operating Income As Reported |
|
-24.02
-40.91%
|
-17.05
-444.84%
|
-3.13
-37.82%
|
-2.27
|
| EBITDA |
|
-18.91
-80.33%
|
-10.49
-277.24%
|
5.92
+327.14%
|
-2.60
|
| Normalized EBITDA |
|
-23.90
-1.08%
|
-23.64
-588.49%
|
4.84
+295.69%
|
-2.47
|
| Reconciled Depreciation |
|
0.07
-62.37%
|
0.19
+115.56%
|
0.09
+46.89%
|
0.06
|
| EBIT |
|
-18.98
-77.74%
|
-10.68
-283.30%
|
5.83
+318.55%
|
-2.67
|
| Total Unusual Items |
|
4.99
-62.09%
|
13.16
+1121.54%
|
1.08
+917.75%
|
-0.13
|
| Total Unusual Items Excluding Goodwill |
|
4.99
-62.09%
|
13.16
+1121.54%
|
1.08
+917.75%
|
-0.13
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-19.18
-72.17%
|
-11.14
-311.44%
|
5.27
+296.45%
|
-2.68
|
| Pretax Income |
|
-19.20
-71.29%
|
-11.21
-312.70%
|
5.27
+296.45%
|
-2.68
|
| Net Non Operating Interest Income Expense |
|
-0.21
+59.51%
|
-0.53
+5.73%
|
-0.56
-3851.56%
|
-0.01
|
| Interest Expense Non Operating |
|
0.21
-59.51%
|
0.53
-5.73%
|
0.56
+3414.30%
|
0.02
|
| Net Interest Income |
|
-0.21
+59.51%
|
-0.53
+5.73%
|
-0.56
-3851.56%
|
-0.01
|
| Interest Expense |
|
0.21
-59.51%
|
0.53
-5.73%
|
0.56
+3414.30%
|
0.02
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
0.00
|
| Interest Income |
|
—
|
—
|
—
|
0.00
|
| Other Income Expense |
|
5.04
-20.87%
|
6.37
-28.91%
|
8.96
+2352.41%
|
-0.40
|
| Other Non Operating Income Expenses |
|
0.05
+100.75%
|
-6.79
-186.17%
|
7.88
+3062.97%
|
-0.27
|
| Gain On Sale Of Security |
|
4.99
-62.09%
|
13.16
+1121.54%
|
1.08
+917.75%
|
-0.13
|
| Gain On Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Tax Provision |
|
0.02
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
1.05
|
0.00
-100.00%
|
0.23
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-19.21
-71.46%
|
-11.21
-312.70%
|
5.27
+296.45%
|
-2.68
|
| Net Income From Continuing Operation Net Minority Interest |
|
-19.18
-72.17%
|
-11.14
-311.44%
|
5.27
+296.45%
|
-2.68
|
| Net Income From Continuing And Discontinued Operation |
|
-19.18
-72.17%
|
-11.14
-311.44%
|
5.27
+296.45%
|
-2.68
|
| Net Income Continuous Operations |
|
-19.21
-71.46%
|
-11.21
-312.70%
|
5.27
+296.45%
|
-2.68
|
| Minority Interests |
|
0.03
-50.00%
|
0.07
|
0.00
|
—
|
| Normalized Income |
|
-23.12
+4.84%
|
-24.30
-649.93%
|
4.42
+273.23%
|
-2.55
|
| Net Income Common Stockholders |
|
-19.18
-72.17%
|
-11.14
-311.44%
|
5.27
+296.45%
|
-2.68
|
| Diluted EPS |
|
-1.91
-26.49%
|
-1.51
-341.13%
|
0.63
+150.81%
|
-1.23
|
| Basic EPS |
|
-1.91
-26.49%
|
-1.51
-341.13%
|
0.63
+150.81%
|
-1.23
|
| Basic Average Shares |
|
10.19
+38.47%
|
7.36
-12.54%
|
8.41
+286.67%
|
2.18
|
| Diluted Average Shares |
|
10.19
+38.47%
|
7.36
-12.54%
|
8.41
+11.47%
|
7.55
|
| Diluted NI Availto Com Stockholders |
|
-19.18
-72.17%
|
-11.14
-308.17%
|
5.35
+299.54%
|
-2.68
|
| Average Dilution Earnings |
|
—
|
0.00
-100.00%
|
0.08
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
6.95
+3.38%
|
6.72
-25.02%
|
8.97
+945.17%
|
0.86
|
| Current Assets |
|
6.08
+7.12%
|
5.68
-25.50%
|
7.62
+1288.87%
|
0.55
|
| Cash Cash Equivalents And Short Term Investments |
|
4.78
+30.09%
|
3.67
-51.80%
|
7.62
+1331.53%
|
0.53
|
| Cash And Cash Equivalents |
|
3.06
-16.78%
|
3.67
-51.80%
|
7.62
+1331.53%
|
0.53
|
| Cash Financial |
|
—
|
—
|
—
|
0.53
|
| Other Short Term Investments |
|
1.72
|
0.00
|
—
|
0.00
|
| Receivables |
|
—
|
—
|
—
|
0.00
|
| Accounts Receivable |
|
—
|
—
|
—
|
0.00
|
| Prepaid Assets |
|
0.99
-48.42%
|
1.93
|
—
|
0.02
|
| Other Current Assets |
|
0.31
+301.30%
|
0.08
|
—
|
—
|
| Total Non Current Assets |
|
0.87
-16.89%
|
1.05
-22.31%
|
1.35
+335.91%
|
0.31
|
| Net PPE |
|
0.84
-19.66%
|
1.05
-22.31%
|
1.35
+335.91%
|
0.31
|
| Gross PPE |
|
1.37
-16.92%
|
1.65
-5.18%
|
1.74
+156.88%
|
0.68
|
| Accumulated Depreciation |
|
-0.53
+12.15%
|
-0.60
-54.10%
|
-0.39
-6.12%
|
-0.37
|
| Machinery Furniture Equipment |
|
0.11
-17.65%
|
0.14
+7.94%
|
0.13
+19.16%
|
0.11
|
| Other Properties |
|
1.26
-16.85%
|
1.51
-6.20%
|
1.61
+182.37%
|
0.57
|
| Non Current Prepaid Assets |
|
0.03
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
6.99
+12.42%
|
6.22
-84.94%
|
41.26
+6.80%
|
38.64
|
| Current Liabilities |
|
3.56
+50.59%
|
2.37
+67.45%
|
1.41
+222.83%
|
0.44
|
| Payables And Accrued Expenses |
|
2.33
+77.56%
|
1.31
+12.64%
|
1.16
+646.56%
|
0.16
|
| Payables |
|
1.93
+159.54%
|
0.74
+28.28%
|
0.58
+289.64%
|
0.15
|
| Accounts Payable |
|
1.93
+159.54%
|
0.74
+28.28%
|
0.58
+304.64%
|
0.14
|
| Other Payable |
|
—
|
—
|
—
|
0.01
|
| Current Accrued Expenses |
|
0.40
-30.21%
|
0.57
-2.92%
|
0.58
+8318.77%
|
0.01
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.81
-5.91%
|
0.86
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.13
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
0.13
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
0.15
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
0.15
|
| Other Current Liabilities |
|
0.42
+120.21%
|
0.19
-22.80%
|
0.25
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
3.42
-11.04%
|
3.85
-90.34%
|
39.85
+4.32%
|
38.20
|
| Long Term Debt And Capital Lease Obligation |
|
3.14
+1072.39%
|
0.27
-92.22%
|
3.44
+105.03%
|
1.68
|
| Long Term Debt |
|
2.95
|
—
|
2.98
+84.48%
|
1.62
|
| Long Term Capital Lease Obligation |
|
0.20
-26.87%
|
0.27
-41.99%
|
0.46
+630.42%
|
0.06
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
36.40
+2.72%
|
35.44
|
| Stockholders Equity |
|
-0.04
-105.77%
|
0.64
+101.98%
|
-32.29
+14.52%
|
-37.78
|
| Common Stock Equity |
|
-4.98
-876.44%
|
0.64
+101.98%
|
-32.29
+14.52%
|
-37.78
|
| Capital Stock |
|
4.94
+494000.00%
|
0.00
|
0.00
-100.00%
|
0.02
|
| Common Stock |
|
0.00
+0.00%
|
0.00
|
0.00
-100.00%
|
0.02
|
| Preferred Stock |
|
4.94
|
0.00
|
—
|
—
|
| Share Issued |
|
10.77
+14.28%
|
9.42
+11.98%
|
8.41
+0.00%
|
8.41
|
| Ordinary Shares Number |
|
10.77
+14.28%
|
9.42
+11.98%
|
8.41
+0.00%
|
8.41
|
| Additional Paid In Capital |
|
58.54
+30.20%
|
44.96
+4991.51%
|
0.88
+36.66%
|
0.65
|
| Retained Earnings |
|
-63.50
-43.28%
|
-44.32
-33.58%
|
-33.18
+13.71%
|
-38.45
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.01
|
0.00
|
—
|
—
|
| Minority Interest |
|
0.00
+100.00%
|
-0.13
|
0.00
|
—
|
| Other Equity Adjustments |
|
-0.01
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
-0.04
-107.28%
|
0.51
+101.57%
|
-32.29
+14.52%
|
-37.78
|
| Total Capitalization |
|
2.91
+353.82%
|
0.64
+102.19%
|
-29.31
+18.94%
|
-36.16
|
| Working Capital |
|
2.52
-23.96%
|
3.31
-46.66%
|
6.21
+5496.59%
|
0.11
|
| Invested Capital |
|
-2.03
-416.85%
|
0.64
+102.19%
|
-29.31
+18.94%
|
-36.16
|
| Total Debt |
|
3.14
+1072.39%
|
0.27
-92.22%
|
3.44
+90.47%
|
1.81
|
| Net Debt |
|
—
|
—
|
—
|
1.08
|
| Capital Lease Obligations |
|
0.20
-26.87%
|
0.27
-41.99%
|
0.46
+141.06%
|
0.19
|
| Net Tangible Assets |
|
-0.04
-105.77%
|
0.64
+101.98%
|
-32.29
+14.52%
|
-37.78
|
| Tangible Book Value |
|
-4.98
-876.44%
|
0.64
+101.98%
|
-32.29
+14.52%
|
-37.78
|
| Derivative Product Liabilities |
|
0.28
-92.10%
|
3.58
|
0.00
-100.00%
|
1.08
|
| Interest Payable |
|
—
|
0.00
|
—
|
—
|
| Preferred Stock Equity |
|
4.94
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-17.95
-4.77%
|
-17.14
-592.12%
|
-2.48
-19.29%
|
-2.08
|
| Cash Flow From Continuing Operating Activities |
|
-17.95
-4.77%
|
-17.14
-592.12%
|
-2.48
-19.29%
|
-2.08
|
| Net Income From Continuing Operations |
|
-19.21
-71.46%
|
-11.21
-312.70%
|
5.27
+296.45%
|
-2.68
|
| Depreciation Amortization Depletion |
|
0.07
-62.37%
|
0.19
+115.56%
|
0.09
+46.89%
|
0.06
|
| Depreciation And Amortization |
|
0.07
-62.37%
|
0.19
+115.56%
|
0.09
+46.89%
|
0.06
|
| Other Non Cash Items |
|
0.65
-11.14%
|
0.74
+0.55%
|
0.73
+393.74%
|
0.15
|
| Stock Based Compensation |
|
3.79
+46.17%
|
2.60
+10280.00%
|
0.03
+251.62%
|
0.01
|
| Operating Gains Losses |
|
-4.73
+64.05%
|
-13.16
-1121.54%
|
-1.08
-899.04%
|
0.13
|
| Gain Loss On Investment Securities |
|
-4.99
+62.09%
|
-13.16
-1121.54%
|
-1.08
-917.75%
|
0.13
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
-100.00%
|
7.02
+192.38%
|
-7.60
-2944.94%
|
0.27
|
| Gain Loss On Sale Of PPE |
|
0.09
|
0.00
|
—
|
0.00
|
| Change In Working Capital |
|
1.47
+144.33%
|
-3.32
-4193.83%
|
0.08
+778.45%
|
-0.01
|
| Change In Receivables |
|
0.00
-100.00%
|
0.07
|
0.00
-100.00%
|
0.00
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.67
+135.31%
|
-1.91
-12012.50%
|
0.02
+961.71%
|
0.00
|
| Change In Payables And Accrued Expense |
|
0.97
+176.61%
|
-1.26
-598.42%
|
0.25
+6602.18%
|
-0.00
|
| Change In Accrued Expense |
|
-0.23
-157.75%
|
0.40
+385.71%
|
-0.14
-4609.05%
|
-0.00
|
| Change In Payable |
|
1.20
+172.07%
|
-1.66
-522.65%
|
0.39
+42910.46%
|
-0.00
|
| Change In Account Payable |
|
1.20
+172.07%
|
-1.66
-522.65%
|
0.39
+18542.05%
|
-0.00
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
0.15
|
| Change In Other Current Liabilities |
|
-0.17
+21.03%
|
-0.21
-13.83%
|
-0.19
-14.52%
|
-0.16
|
| Investing Cash Flow |
|
-0.06
-168.18%
|
-0.02
+95.63%
|
-0.50
-151.38%
|
0.98
|
| Cash Flow From Continuing Investing Activities |
|
-0.06
-168.18%
|
-0.02
+95.63%
|
-0.50
-151.38%
|
0.98
|
| Net PPE Purchase And Sale |
|
-0.06
-168.18%
|
-0.02
+95.63%
|
-0.50
-5105.54%
|
-0.01
|
| Purchase Of PPE |
|
-0.06
-168.18%
|
-0.02
+95.63%
|
-0.50
-5105.54%
|
-0.01
|
| Capital Expenditure |
|
-0.06
-168.18%
|
-0.02
+95.63%
|
-0.50
-5105.54%
|
-0.01
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
0.99
|
| Sale Of Investment |
|
—
|
—
|
—
|
0.99
|
| Gain Loss On Sale Of Business |
|
0.17
|
0.00
|
—
|
0.00
|
| Financing Cash Flow |
|
17.41
+31.79%
|
13.21
+31.24%
|
10.07
+667.26%
|
1.31
|
| Cash Flow From Continuing Financing Activities |
|
17.41
+31.79%
|
13.21
+31.24%
|
10.07
+667.26%
|
1.31
|
| Net Issuance Payments Of Debt |
|
4.91
+70.89%
|
2.88
-71.40%
|
10.05
+668.71%
|
1.31
|
| Issuance Of Debt |
|
4.91
+61.45%
|
3.04
-69.87%
|
10.10
+102.00%
|
5.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.17
-250.00%
|
-0.05
+98.70%
|
-3.69
|
| Long Term Debt Issuance |
|
4.91
+61.45%
|
3.04
-69.87%
|
10.10
+102.00%
|
5.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.17
-250.00%
|
-0.05
+98.70%
|
-3.69
|
| Net Long Term Debt Issuance |
|
4.91
+70.89%
|
2.88
-71.40%
|
10.05
+668.71%
|
1.31
|
| Net Common Stock Issuance |
|
7.54
+50.88%
|
5.00
|
0.00
-100.00%
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.01
-99.70%
|
5.00
+33233.33%
|
0.01
|
—
|
| Net Other Financing Charges |
|
—
|
0.34
|
—
|
—
|
| Changes In Cash |
|
-0.60
+84.75%
|
-3.95
-155.69%
|
7.09
+3160.14%
|
0.22
|
| Effect Of Exchange Rate Changes |
|
-0.01
|
0.00
|
—
|
—
|
| Beginning Cash Position |
|
3.67
-51.80%
|
7.62
+1332.14%
|
0.53
+68.97%
|
0.31
|
| End Cash Position |
|
3.06
-16.78%
|
3.67
-51.80%
|
7.62
+1331.53%
|
0.53
|
| Free Cash Flow |
|
-18.01
-4.98%
|
-17.16
-475.81%
|
-2.98
-42.90%
|
-2.09
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.02
|
| Common Stock Issuance |
|
7.54
+50.88%
|
5.00
|
0.00
-100.00%
|
0.00
|
| Issuance Of Capital Stock |
|
12.48
+149.68%
|
5.00
|
0.00
-100.00%
|
0.00
|
| Net Preferred Stock Issuance |
|
4.94
|
0.00
|
—
|
0.00
|
| Preferred Stock Issuance |
|
4.94
|
0.00
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-21 View
- 42026-04-21 View
- 42026-04-21 View
- 8-K2026-03-25 View
- 10-K2026-03-25 View
- 42026-03-24 View
- 8-K2026-03-23 View
- 42026-03-20 View
- 42026-02-17 View
- 42026-02-17 View
- 42026-02-17 View
- 42026-02-17 View
- 42026-02-03 View
- 42026-01-29 View
- 8-K2026-01-28 View
- 42026-01-23 View
- 42026-01-21 View
- 8-K2026-01-15 View
- 42026-01-14 View
- 42026-01-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|